Allena pharmaceuticals, inc. (ALNA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15
Cash flows from operating activities:
Net loss

-47,339

-35,648

-21,650

-24,507

-

Net loss

-

-

-

-

-14,247

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense

2,989

2,049

517

251

207

Depreciation expense

163

78

73

46

98

Non-cash interest expense

8

161

351

204

167

Non-cash lease expense

486

-

-

-

-

Amortization of premium on investments

-

-

33

153

-

Loss on extinguishment of debt

-

-617

-

-

-

Loss on disposal of equipment

-

-

-

-

-7

Change in fair value of warrant liability

-

-

257

132

36

Changes in assets and liabilities:
Prepaid expenses and other current assets

202

1,287

984

-343

639

Other assets

-123

34

89

-

-

Accounts payable

972

441

199

-525

1,001

Accrued expenses

-301

1,764

228

-

-

Accrued expenses

-

-

-

689

219

Operating lease liabilities

-531

-

-

-

-

Other liabilities

-

20

-

-180

-24

Net cash used in operating activities

-43,632

-31,839

-21,065

-23,394

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-13,175

Purchases of property and equipment

122

318

57

102

-

Purchases of investments

-

-

1,247

53,210

-

Maturities of investments

-

-

24,721

29,550

-

Sale of property and equipment

-

-

-

-

5

Net cash used in investing activities

-122

-318

23,417

-23,762

5

Cash flows from financing activities:
Proceeds from (payments of issuance costs) the issuance of common stock, net of issuance costs

12,035

-309

67,197

-

-

Proceeds from exercise of stock options

36

139

28

19

7

Proceeds from issuance of stock through ESPP

76

34

-

-

-

Proceeds from loan payable

-

10,000

-

10,000

3,250

Repayment of loan payable

-

10,492

333

6,256

744

Debt issuance costs paid

-

33

-

368

-

Other

-29

-33

-

-

-

Net cash (used in) provided by financing activities

12,118

-694

66,892

3,395

-

Net decrease in cash and cash equivalents

-31,636

-32,851

69,244

-43,761

-

Supplemental disclosures:
Cash paid for interest

543

906

452

-

-

Net cash (used in) provided by financing activities

-

-

-

-

55,295

Net (decrease) increase in cash and cash equivalents

-

-

-

-

42,125

Cash paid for interest

-

-

-

472

193

Property and equipment purchases included in accounts payable

-

72

11

38

9

Right-of-use assets obtained in exchange of operating lease obligations

992

-

-

-

-

Issuance costs included in accounts payable and accrued expenses

45

-

199

-

-

Issuance of warrants in connection with loan payable

-

-

-

67

7

Accretion of convertible preferred stock to redemption value

-

-

58

69

37